miRNAs与肝细胞癌发生研究进展

doi:10.3969/j.issn.1672-5069.2014.02.031

Abstract

Abstract: MicroRNAs（miRNAs） are a class of 21 to 25 nucleotides non-coding small RNAs that regulate post-transcriptionally gene expression. Recent findings show that the abnormal expression of miRNAs is closely related to a number of diseases，especially the development of malignant tumor. miRNAs are expressed at different levels in various cancers.Studies shows that miRNAs can be used as biological markers for histological classification，prognosis and early diagnosis of hepatocellular carcinoma，and are expected to become a new therapeutic target in vivo. In this paper，a number of known small miRNAs are reviewed for their effect in carcinogenesis in liver cancer.

Key words: Hepatocellular carcinoma, MicroRNAs, Diagnosis, Treatment

Pei Liling，Li Jiansheng，Ren Weihua.. Progress in microRNAs in the development of hepatocellular carcinoma[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(2): 221-224.

References

[1] Parkin DM，Bray F，Ferlay J，et al. Global cancer statistics， 2002. CA Cancer J Clin，2005，55（2）:74-108.
[2] Liu X，Ru J，Zhang J，et al. miR-23a targets interferon regulatory factor 1 and modulates cellular proliferation and paclitaxel-induced apoptosis in gastric adenocarcinoma cells. PLoS One，2013，8（6）:e64707.
[3] Kuo PL，Liao SH，Hung JY，et al. MicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein. Biochim Biophys Acta，2013，1830 （6）:3756-3766.
[4] Tang W，Zhu J，Su S，et al. MiR-27 as a prognostic marker for breast cancer progression and patient survival. PLoS One，2012，7（12）:e51702.
[5] Pineau P，Volinia S，McJunkin K，et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA，2010，107（1）:264-269.
[6] Galardi S，Mercatelli N，Giorda E，et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27 kip1. J Biol Chem，2007，282（32）:23716-23724.
[7] Fornari F，Gramantieri L，Ferracin M，et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene，2008，27（43）:5651-5661.
[8] Medina R，Zaidi SK，Liu CG，et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res， 2008，68（8）:2773-2780.
[9] Bai S，Nasser MW，Wang B，et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem，2009，284（46）:32015-32027.
[10] Xu J，Zhu X，Wu L，et al. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway. Liver Int，2012，32（5）:752-760.
[11] Law PT，Qin H，Ching AK，et al. Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma. J Hepatol，2013，58（6）:1165-1173.
[12] Chen P，Zhao X，Ma L. Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem，2013 Jul 11[Epub ahead of print].
[13] Yang H，Fang F，Chang R，et al. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting TGFBR1 and FGF9 in hepatocellular carcinoma. Hepatology，2013，58（1）:205-217.
[14] Zhou B，Ma R，Si W，et al .MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett，2013，333（2）:159-169.
[15] Zhou J，Wang W. Analysis of microRNA expression profiling identifies microRNA-503 regulates metastatic function in hepatocellular cancer cell. J Surg Oncol，2011，104（3）:278-283.
[16] Bihrer V，Waidmann O，Friedrich-Rust M，et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One，2011，6（10）:e26971.
[17] Tomimaru Y，Eguchi H，Nagano H，et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol，2012，56（1）:167-175.
[18] Li L，Guo Z，Wang J，et al. Serum miR-18a:a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci，2012，57（11）:2910-2916.
[19] Li LM，Hu ZB，Zhou ZX，et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res，2010，70（23）:9798-9807. [20] Zhou J，Yu L，Gao X，et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol，2011，29（36）:4781-4788.
[21] Bruix J，Sherman M. Management of hepatocellular carcinoma. Hepatology，2005，42（5）:1208-1236.
[22] Bruix J，Sherman M，Llovet JM，et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol，2001，35（3）:421-430.
[23] Leung TW，Tang AM，Zee B，et al. Construction of the Chinese university prognostic index for hepatocellular carcinoma and comparison with the TNM staging system，the Okuda staging system，and the cancer of the liver Italian program staging system:a study based on 926 patients. Cancer，2002，94（6）:1760-1769.
[24] Budhu A，Jia HL，Forgues M，et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology，2008，47（3）:897-907.
[25] Li W，Xie L，He X，et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer，2008，123（7）:1616-1622.
[26] Fornari F，Gramantieri L，Giovannini C，et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res，2009， 69（14）:5761-5767.
[27] Zhang J，Yang Y，Yang T，et al. microRNA-22，downregulated in hepatocellular carcinoma and corrlated with prognosis，suppresses cell proliferation and tumourigenicity. Br J Cancer，2010，103（8）:1215-1220.
[28] Wong CC，Wong CM，Tung EK，et al. The MicroRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-Kinase 2. Gastroenterology，2011，140（1）:322-331.
[29] Gramantieri L，Fornari F，Ferracin M，et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res，2009，15（16）:5073-5081.
[30] Kota J，Chivukula RR，O'Donnell KA，et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell，2009，137（6）:1005-1017.
[31] Ji J，Shi J，Budhu A，et al. MicroRNA expression， survival，and response to interferon in liver cancer. N Engl J Med，2009，361（15）:1437-1447.
[32] Marquez RT，Wendlandt E，Galle CS，et al. MicroRNA-21 is upregulated during the proliferative phase of liver regeneration，targets Pellino-1，and inhibits NF-kappa B signaling. Am J Physiol Gastrointest Liver Physiol，2010，298（4）:G535-G541.

Progress in microRNAs in the development of hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[2]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[3]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[4]	Zeng Yanni, Zhang Can, Bi Junying, et al.. Value of long-time delayed enhancement scan of MRI in the diagnosis of solitary necrotic nodule of liver [J]. Journal of Practical Hepatology, 2019, 22(6): 900-903.
[5]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[6]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[7]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[8]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[9]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[10]	Zhu Jun, Ding Ying, Wang Shiqing, et al. Peripheral blood Th22 cells and plasma interleukin-22 level changes in patients with hepatocellular carcinoma after hepatectomy and administration of ulinastatin [J]. Journal of Practical Hepatology, 2019, 22(5): 720-723.
[11]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[12]	Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases [J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.
[13]	Cheng Hua, Ju Hui, Song Deshun et al. Value of serum angiopoietin-like protein 2 and Golgi protein 73 levels in the diagnosis of hepatic fibrosis in patient with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 494-497.
[14]	Yu Yingfang, Wen Shengbao. Assessment of liver fibrosis with diffusion-weighted magnetic resonance imaging using single, double and stretch index model in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 502-505.
[15]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.